Navigation Links
endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money By Rapidly Deploying Studies With Custom Reporting
Date:10/19/2010

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Response Technology (IRT) development, today announced the release of PULSE 2.0™. endpoint PULSE is a proprietary platform that enables the configuration of fully validated, custom IRT systems for clinical trials in a fraction of the time required by traditional development. New in PULSE 2.0 is the ability for project managers to create and manage client-specific templates, ensuring that every study endpoint develops automatically contains the client's preferred configurations. PULSE 2.0 also offers enhanced reports and administrative functionality, with a focus on improved control over clinical supplies.

endpoint's PULSE configurable architecture meets Clinical Program Managers' demands for making mid-study changes quickly and easily. endpoint's PULSE platform combines IRT capabilities with pre-validated modules allowing clinical trials to move ahead at a more rapid rate due to project managers having access to the configurable design elements rather than relying on custom development for each change.

"Since launching PULSE in February, we've been compiling a long list of new features and functionality," said Jonathan Dole, co-founder and CEO, endpoint. "PULSE 2.0 is a blend of features our customers are asking for and new tools that enable us to deliver an even more robust IRT system in the same timeframe to which our customers are becoming accustomed."

About endpoint

endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.


'/>"/>
SOURCE endpoint
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
7. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
10. Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
(Date:2/23/2017)... ... Research and Markets has announced the addition of the "Global ... report to their offering. The Global Antifungal Drugs Market ... next decade to reach approximately $12.8 billion by 2025. ... the given segments on global as well as regional levels presented in ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist ... Throughout the month of February, patients who visit Hamlin Dental Group will receive a ... for two at the Cheesecake Factory. , Tickets are available for routine dental ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in clinical trials, today announced that Premier Research, a leading clinical development service ... Clinical trials are becoming increasingly complex, due in part to an array of ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
Breaking Medicine News(10 mins):